Abstract
There has been a proliferation of prognostic factors in breast cancer. Currently there are at least 76 putative breast cancer prognostic factors reported in humans. In this chapter the literature for 37 factors is reviewed. The factors that are supported in the literature are not necessarily the final prognostic factors for breast cancer. They deserve further study in an integrative model. The prognostic factors are presented in three tables, each representing a level of analysis, i.e., epidemiologic, anatomic-cellular, and molecular-genetic.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Ansell D, Whitman S, Lipton R, Cooper R (1993) Race, income, and survival from breast cancer at two public hospitals. Cancer 72: 2974–2978
Barraclough J, Pinder P, Cruddas M, Osmond C, Taylor I, Perry M (1992) Life events and breast cancer prognosis. BMJ 304: 1078–1081
Bastarrachea J, Hortobagyi GN, Smith TL, Kau SC, Buzdar AU (1993) Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med 119: 18–25
Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ (eds) (1992) Manual for staging of cancer, 4th edn. Lippincott, Philadelphia
Berger U, McClelland RA, Wilson P, Greene GL, Haussler MR, Oike JW et al (1991) Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25–dihydroxyvitamin D3 receptor in breast cancer and the relationship to prognosis. Cancer Res 51: 239–244
Bianchi S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi R et al (1993) Prognostic value of proliferating cell nuclear antigen in lymph node-negative breast cancer patients. Cancer 72: 120–125
Bloom H, Richardson W (1957) Histological grading and prognosis in breast cancer. Br J Cancer 9: 359–377
Burke HB, Henson DE (1993) Criteria for prognostic factors and for an enhanced prognostic system. Cancer 72: 3131–3135
Carter CL, Allen C, Henson DE (1988) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63: 181–187
Ciocca DR, Clark GM, Tandon AK, Fuqua SAW, Welch WJ, McGuire WL (1993) Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implica¬tions. J Natl Cancer Inst 85: 570–574
Ciocca DR, Luque EH (1991) Immunological evidence for the identity between the hsp27 estrogen-regulated heat shock protein and the p29 estrogen receptor-associated protein in breast and endometrial cancer. Breast Cancer Res 20: 33–42
Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SAW (1993) Biological and clinical implications of heat shock protein 27 000 (Hsp27): a review. J Natl Cancer Inst 85: 1558–1570
Clayton F, Hopkins CL (1993) Pathologic correlates of prognosis in lymph node-positive breast carcinomas. Cancer 67: 11780–11790
Coates A, Gebski V, Signorini D, Murray P, McNeil D, Byrne M et al (1992) Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. J Clin Oncol 10: 1833–1838
Davidoff AM, Herndon JE, Glover NS, Kerns BM, Pence JC, Inglehart JD, Marks JR (1991) Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 110: 259–264
Fisher B, Redmond C, Fisher ER, Caplan R (1988) Relative worth of estrogen and progesterone receptors and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients. J Clin Oncol 6: 1076–1087
Foekens JA, van Putten WJ, Portengen H, de Koning H, Thirion B, Alexieva-Figusch J, Klijn JM (1993) Prediction of relapse and survival in breast cancer patients by pS2 protein status. J Clin Oncol 11: 899–908
Game JP, Aspegren K, Linell F, Rank F, Ranstam J (1994) Primary prognostic factors in invasive breast carcinoma with special reference to ductal carcinoma and histologic malignancy grade. Cancer 73: 1438–1448
Gaspirini G, Weidner N, Bevilacqua P, Maluta S, Palma PD, Caffo O et al (1994) Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic invasion are rel¬evant prognostic markers in node-negative breast carcinoma. J Clin Oncl 12: 454–466
Gilchrist KW, Gray R, Fowble B, Tormey DC, Taylor SG (1993) Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow- up study of 728 eastern cooperative oncology group patients. J Clin Oncol 11: 1929–1935
Gilchrist KW, Kalish L, Gould VE, Hirschl S, Imbriglia JE, Levy WM et al (1985) Interobserver reproducibility of histopathology features in stage II breast cancer: an ECOG study. Breast Cancer Res Treat 5: 3 - 10
Gion M, Mione R, Pappagallo GL, Gatti C, Nascimben O, Brandes A et al (1992) Tissue polypeptide antigen in breast cancer cytosol: a new effective prognostic factor. Eur J Cancer 29A: 66 - 69
Going J J, Anderson TJ, Wyllie AH (1992) Ras p21 in breast tissue: association with pathology and cellular localization. Br J Cancer 65: 45–50
Gullick WJ (1991) Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 47: 87–98
Hahnel R (1983) Oestrogen receptors and breast carcinoma. Med J Aust 1: 350–351
Hennessy C, Henry JA, May FEB, Westley BR, Angus B, Lennard TW (1991) Expression of the antimetastatic gene nm23 in human breast cancer: association with good prognosis. J Natl Cancer Inst 83: 281–285
Henson DE, Ries L, Freedman LS, Carriaga M (1991) Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. Cancer 68: 2142–2149
Hermanek P, Sobin LH (eds) (1992) UICC TNM classification of malignant tumours, 4th edn, 2nd revision. Springer, Berlin Heidelberg New York Tokyo
Ip C (1993) Controversial issues of dietary fat and experimental mammary carcinogenesis. Prev Med 22: 728–737
Joensuu H, Toikkanen S (1992) Identification of subgroups with favorable prognosis in breast cancer. Acta Oncol 31: 293–301
Kamby C (1990) The pattern of metastases in human breast cancer: methodologic aspects and influence of prognostic factors. Cancer Res Treat 17: 37–61
Kandalaft PL, Chang KL, Ahn CW, Traweek ST, Mehta P, Battifora H (1993) Prognostic significance of immunohistochemical analysis of Cathepsin D in low-stage breast cancer. Cancer 71: 2756–2763
Komitowski D, Janson C (1990) Quantitative features of chromatin structure in the prognosis of breast cancer. Cancer 65: 2725–2730
Lipton A, Santen RJ, Santner SJ, Harvey HA, Sanders SI, Matthews MA (1992) Prognostic value of breast cancer aromatase. Cancer 70: 1951–1955
Mansour O, Motawi T, Khaled H, el-Ahmady O (1993) Clinical value of thymidine kinase and tissue polypeptide specific antigen in breast cancer. Dis Markers 11: 171–177
McGuire WL, Clark GM (1992) Prognostic factors and treatment decisions in axillary-node- negative breast cancer. N Engl J Med 326: 1756–1761
McGuire WL, Clark GM, Dressier LG, Owens MA (1986) Role of steroid hormone receptors as prognostic factors in primary breast cancer. NCI Monogr 1: 1–23
McGuire WL, Jackson JG, Figueroa JA, Shimasaki S, Powell DR, Yee D (1992) Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action. J Natl Cancer Inst 84: 1336–1341
Meyer JS, Koehm SL, Hughes JM, Higa E, Wittliff JL, Lagos JA, Manes JL (1993) Bromo- deoxyuridine labeling for S-phase measurement in breast carcinoma. Cancer 71: 3531–3540
Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J (1994) Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 86: 356–361
O’Neill KL, Hoper M, Odling-Smee GW (1992) Can thymidine kinase levels in breast tumors predict disease recurrence? J Natl Cancer Inst 84: 1825–1828
O’Sullivan C, Lewis CE, Harris AL, McGee JO (1993) Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet 342: 148–149
Perren TJ (1991) c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 63: 328–332
Pertschuk LP, Feldman JG, Kim DS, Nayeri K, Eisenberg KB, Carter AC et al (1993) Steroid hormone receptor immunochemistry and amplification of c-myc protooncogene. Cancer 71: 162 - 171
Pollak M, Costantino J, Polychronakos C, Blauer S, Guyda H, Redmond C et al (1990) Effects of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 82: 1693–1697
Ravdin PM, Tandon AK, Allred DC, Clark GM, Fuqua AW, Hilsenbeck SH et al (1994) Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 12: 467–474
Ries LA, Henson DE, Harras A (1994) Survival from breast cancer according to tumor size and nodal status. Semin Surg Oncol 3: 35–53
Rio MC, Chambon P (1990) The pS2 gene, mRNA and protein: a potential marker for human breast cancer. Cancer Cells 2: 269–274
Rochefordiere AD, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR et al (1993) Age as prognostic factor in premenopausal breast carcinoma. Lancet 341: 1039–1043
Royds JA, Stephenson TJ, Rees RC, Shorthouse AJ, Silcocks PB (1993) Nm23 protein expres¬sion in ductal in situ and invasive human breast carcinoma. J Natl Cancer Inst 85: 727–731
Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL (1987) Epidermal-growth- factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1 (8547): 1398–1402
Satariano WA, Ragland DR (1994) The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120: 104–110
Schneider E, Horton JK, Yang CH, Nakagawa M, Cowen KH (1994) Multidrug resistance- associated protein gene overexpression and reduced drug sensitivity to topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54: 152–158
Scholl SM, Pallud C, Beuvon F, Hacene K, Stanley ER, Rohtschneider L et al (1994) Anti- colony-stimulating-factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 86: 120–126
Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V Et Al (1993) p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85: 965–970
Silvestrini R, Daidone MG, Gasparini G (1985) Cell kinetics as a prognostic marker in node- negative breast cancer. Cancer 56: 1982–1987
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182
Spandidos DA, Agnantis NJ (1984) Human malignant tumours of the breast, as compared to their respective normal tissue, have elevated expression of the Hervey ras oncogene. Anticancer Res 4: 269–272
Steele GD, Winchester DP, Menck HR, Murphy GP (eds) (1993) National Cancer Data Base annual review of patient care, 1993. American Cancer Society, Atlanta
Stenman U, Heikkinen R (1991) Serum markers for breast cancer. Scand J Clin Lab Invest 206: 52–59
Thor A, Benz C, Moore D, Goldman E, Edgerton S, Landry J et al (1991) Stress response protein (srp–27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. J Natl Cancer Inst 83: 170–178
Thorpe SM, Rose C (1986) Oestrogen and progesterone receptor determinations in breast cancer: technology and biology. Cancer Serv 5: 505–525
Tuccari G, Rizzo A, Giuffre G, Barresi G (1993) Immunohistochemical detection of DNA topoisomerase type II in primary breast carcinomas: correlation with clinico-pathological features. Virchows Arch [A] 423: 51–55
Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P et al (1993) Proliferation index as a prognostic marker in breast cancer. Cancer 71: 3926–3931
Watson PH, Safneck JR, Le K, Dubik D, Shiu RPC (1993) Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis. J Natl Cancer Inst 85: 902–907
Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH et al (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast cancer. J Natl Cancer Inst 84: 1875–1887
Weikel W, Beck T, Mitze M, Knapstein PG (1991) Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat 18: 149–154
Werner M, Faser C, Silverberg M (1993) Clinical utility and validation of emerging biochemical markers for mammary adenocarcinoma. Clin Chem 39: 2386–2396
Yahan SR, Neuberg DS, DiefTenbach A, Yacoub L (1993) Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer 71: 3552–3559
Yates JW, Chalmer B, McKegney FP (1980) Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 45: 2220–2224
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 International Union Against Cancer, Geneva
About this chapter
Cite this chapter
Burke, H.B., Hutter, R.V.P., Henson, D.E. (1995). Breast Carcinoma. In: Hermanek, P., Gospodarowicz, M.K., Henson, D.E., Hutter, R.V.P., Sobin, L.H. (eds) Prognostic Factors in Cancer. UICC International Union Against Cancer / Union Internationale Contre le Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79395-0_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-79395-0_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-58688-3
Online ISBN: 978-3-642-79395-0
eBook Packages: Springer Book Archive